10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
ContraFect's 10-Year ROIIC % for the quarter that ended in Dec. 2022 was 1,850.66%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for ContraFect's 10-Year ROIIC % or its related term are showing as below:
CFRXQ's 10-Year ROIIC % is ranked better than 97.58% of 1362
companies
in the Biotechnology industry
Industry Median: -33.885
vs CFRXQ: 1850.66
ContraFect 10-Year ROIIC % Historical Data
The historical data trend for ContraFect's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ContraFect's 10-Year ROIIC %
For the Biotechnology subindustry, ContraFect's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ContraFect's 10-Year ROIIC % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ContraFect's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where ContraFect's 10-Year ROIIC % falls into.
ContraFect 10-Year ROIIC % Calculation
ContraFect's 10-Year ROIIC % for the quarter that ended in Dec. 2022 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( -56.889 (Dec. 2022) - -19.154 (Dec. 2012) )
/
( 5.32 (Dec. 2022) - 7.359 (Dec. 2012) )
=
-37.735
/
-2.039
=
1,850.66%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
ContraFect 10-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of ContraFect's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CFRXQ has been successfully added to your 